Noveris Health Sciences is trading at $0.12, +8.70% now, with no clear September 8, 2026 catalyst identified.
- Recent company disclosures include Q2 net income of $22,811 and a six-month net loss of $1,593,691.
- The company proposed C$500,000 in convertible-debenture financing.
- Broader markets are declining, so the gain does not align clearly with market direction.